Literature DB >> 31221660

Tumor microenvironment and clonal monocytes from chronic myelomonocytic leukemia induce a procoagulant climate.

Johanna Zannoni1, Natacha Mauz1,2, Landry Seyve3,4, Mathieu Meunier1,2, Karin Pernet-Gallay5, Julie Brault3,6, Claire Jouzier1,2, David Laurin1,7, Mylène Pezet8, Martine Pernollet9, Jean-Yves Cahn2, Fabrice Cognasse10,11, Benoît Polack3,4, Sophie Park1,2.   

Abstract

Chronic myelomonocytic leukemia (CMML) is a myeloid hematological malignancy with overlapping features of myelodysplastic syndromes (MDSs) and myeloproliferative neoplasms (MPNs). The knowledge of the role of the tumor microenvironment (TME), particularly mesenchymal stromal cells (MSCs), in MDS pathogenesis is increasing. Generally, cancer is associated with a procoagulant state participating in tumor development. Monocytes release procoagulant, tissue factor (TF)-bearing microparticles. We hypothesized that MSCs and clonal monocytes release procoagulant extracellular vesicles (EVs) within the CMML TME, inducing a procoagulant state that could modify hematopoietic stem cell (HSC) homeostasis. We isolated and cultured MSCs and monocytes from CMML patients and MSCs from healthy donors (HDs). Their medium EVs and small EVs (sEVs) were collected after iterative ultracentrifugations and characterized by nanoparticle tracking analysis. Their impact on hemostasis was studied with a thrombin generation assay and fibrinography. CMML or HD HSCs were exposed to sEVs from either CMML or HD MSCs. CMML MSC sEVs increased HD HSC procoagulant activity, suggesting a transfer of TF from the CMML TME to HD HSCs. The presence of TF on sEVs was shown by electron microscopy and western blot. Moreover, CMML monocyte EVs conferred a procoagulant activity to HD MSCs, which was reversed by an anti-TF antibody, suggesting the presence of TF on the EVs. Our findings revealed a procoagulant "climate" within the CMML environment related to TF-bearing sEVs secreted by CMML MSCs and monocytes.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31221660      PMCID: PMC6595258          DOI: 10.1182/bloodadvances.2018026955

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  52 in total

1.  Nanostructure of the fibrin clot.

Authors:  C Yeromonahos; B Polack; F Caton
Journal:  Biophys J       Date:  2010-10-06       Impact factor: 4.033

2.  A quantitative study of monocyte procoagulant activity in acute monoblastic and chronic myelomonocytic leukaemias.

Authors:  M J Auger; M J Mackie
Journal:  Acta Haematol       Date:  1987       Impact factor: 2.195

Review 3.  Microparticles and Fibrinolysis.

Authors:  Loris Vallier; Sylvie Cointe; Romaric Lacroix; Amandine Bonifay; Coralie Judicone; Françoise Dignat-George; Hau C Kwaan
Journal:  Semin Thromb Hemost       Date:  2016-12-06       Impact factor: 4.180

4.  Procoagulant activity of human mesenchymal stem cells.

Authors:  Barbara A Christy; Maryanne C Herzig; Robbie K Montgomery; Christopher Delavan; James A Bynum; Kristin M Reddoch; Andrew P Cap
Journal:  J Trauma Acute Care Surg       Date:  2017-07       Impact factor: 3.313

5.  Expression of the proliferation-associated nuclear protein MIB-1 and its relationship with microvascular density in bone marrow biopsies of patients with myelodysplastic syndromes.

Authors:  Michael G Alexandrakis; Freda H Passam; Despina S Kyriakou; Constantina Dambaki; George Katrinakis; George Tsirakis; John Konsolas; Efstathios N Stathopoulos
Journal:  J Mol Histol       Date:  2004-11       Impact factor: 2.611

Review 6.  Bleeding complications in patients with hematologic malignancies.

Authors:  Massimo Franchini; Francesco Frattini; Silvia Crestani; Carlo Bonfanti
Journal:  Semin Thromb Hemost       Date:  2012-12-17       Impact factor: 4.180

7.  Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes.

Authors:  Michael G Alexandrakis; Freda H Passam; Constantina A Pappa; Katerina Sfiridaki; George Tsirakis; John Damilakis; Efstathios N Stathopoulos; Despina S Kyriakou
Journal:  Leuk Res       Date:  2005-01       Impact factor: 3.156

8.  Angiogenesis in myelodysplastic syndromes.

Authors:  G Pruneri; F Bertolini; D Soligo; N Carboni; A Cortelezzi; P F Ferrucci; R Buffa; G Lambertenghi-Deliliers; F Pezzella
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

Review 9.  Interaction of MSC with tumor cells.

Authors:  Catharina Melzer; Yuanyuan Yang; Ralf Hass
Journal:  Cell Commun Signal       Date:  2016-09-08       Impact factor: 5.712

10.  Microvesicles from Mesenchymal Stromal Cells Are Involved in HPC-Microenvironment Crosstalk in Myelodysplastic Patients.

Authors:  Sandra Muntión; Teresa L Ramos; María Diez-Campelo; Beatriz Rosón; Luis Ignacio Sánchez-Abarca; Irena Misiewicz-Krzeminska; Silvia Preciado; María-Eugenia Sarasquete; Javier de Las Rivas; Marcos González; Fermín Sánchez-Guijo; María-Consuelo Del Cañizo
Journal:  PLoS One       Date:  2016-02-02       Impact factor: 3.240

View more
  4 in total

Review 1.  Tumor Microenvironment Uses a Reversible Reprogramming of Mesenchymal Stromal Cells to Mediate Pro-tumorigenic Effects.

Authors:  Armel H Nwabo Kamdje; Paul F Seke Etet; Richard Simo Tagne; Lorella Vecchio; Kiven Erique Lukong; Mauro Krampera
Journal:  Front Cell Dev Biol       Date:  2020-11-19

Review 2.  Emerging data supporting stromal cell therapeutic potential in cancer: reprogramming stromal cells of the tumor microenvironment for anti-cancer effects.

Authors:  Armel H Nwabo Kamdje; Paul F Seke Etet; Richard Tagne Simo; Lorella Vecchio; Kiven Erique Lukong; Mauro Krampera
Journal:  Cancer Biol Med       Date:  2020-12-15       Impact factor: 4.248

Review 3.  TA-MSCs, TA-MSCs-EVs, MIF: their crosstalk in immunosuppressive tumor microenvironment.

Authors:  Zhenghou Zhang; Xiangyu Zhou; Jinshuai Guo; Fusheng Zhang; Yiping Qian; Guang Wang; Meiqi Duan; Yutian Wang; Haiying Zhao; Zhi Yang; Zunpeng Liu; Xiaofeng Jiang
Journal:  J Transl Med       Date:  2022-07-16       Impact factor: 8.440

Review 4.  The "Vesicular Intelligence" Strategy of Blood Cancers.

Authors:  Dorian Forte; Martina Barone; Francesca Palandri; Lucia Catani
Journal:  Genes (Basel)       Date:  2021-03-13       Impact factor: 4.096

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.